These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 2513038)

  • 1. Osteoporosis and immunosuppression in multiple myeloma.
    Farrell AM; Powell RJ
    BMJ; 1989 Nov; 299(6708):1164. PubMed ID: 2513038
    [No Abstract]   [Full Text] [Related]  

  • 2. Osteoporosis and immunosuppression in multiple myeloma.
    Dolan AL; Wheeler TK; Jones DH; Crisp AJ
    BMJ; 1989 Sep; 299(6701):718-9. PubMed ID: 2508886
    [No Abstract]   [Full Text] [Related]  

  • 3. Regulatory B cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu.
    Zhang L; Tai YT; Ho M; Xing L; Chauhan D; Gang A; Qiu L; Anderson KC
    Blood Cancer J; 2017 Mar; 7(3):e547. PubMed ID: 28338671
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunodeficiency and immunotherapy in multiple myeloma.
    Pratt G; Goodyear O; Moss P
    Br J Haematol; 2007 Sep; 138(5):563-79. PubMed ID: 17686051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma.
    Feng X; Zhang L; Acharya C; An G; Wen K; Qiu L; Munshi NC; Tai YT; Anderson KC
    Clin Cancer Res; 2017 Aug; 23(15):4290-4300. PubMed ID: 28249894
    [No Abstract]   [Full Text] [Related]  

  • 6. The gravity of it all: From osteoporosis to immunosuppression, exploring disease in a microgravity environment holds promise for better treatments on Earth.
    Roberge E
    IEEE Pulse; 2014; 5(4):35-41. PubMed ID: 25029680
    [No Abstract]   [Full Text] [Related]  

  • 7. Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression.
    Wang J; De Veirman K; Faict S; Frassanito MA; Ribatti D; Vacca A; Menu E
    J Pathol; 2016 Jun; 239(2):162-73. PubMed ID: 26956697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunosuppression and infection in multiple myeloma.
    Jacobson DR; Zolla-Pazner S
    Semin Oncol; 1986 Sep; 13(3):282-90. PubMed ID: 3532328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple myeloma without paraprotein.
    Szücs J
    Haematologia (Budap); 1970; 4(1):97-102. PubMed ID: 5522360
    [No Abstract]   [Full Text] [Related]  

  • 10. Immune alterations in untreated and treated multiple myeloma.
    Dasanu CA
    J Oncol Pharm Pract; 2012 Jun; 18(2):257-63. PubMed ID: 21859744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Studies on the function of monocytes from patients with multiple myeloma. III. Relationship between alpha-glycoprotein and the suppressor function of monocytes].
    Funato T; Watanabe Y; Hayashi M; Koide A; Hirasawa Y; Ohtani H; Saito M
    Rinsho Ketsueki; 1984 Jan; 25(1):9-16. PubMed ID: 6205178
    [No Abstract]   [Full Text] [Related]  

  • 12. Graft-versus-myeloma after withdrawal of immunosuppression following allogeneic peripheral stem cell transplantation.
    Libura J; Hoffmann T; Passweg J; Gregor M; Favre G; Tichelli A; Gratwohl A
    Bone Marrow Transplant; 1999 Oct; 24(8):925-7. PubMed ID: 10516707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there an association between multiple myeloma and prostate cancer?
    Kao J; Jani AB; Vijayakumar S
    Med Hypotheses; 2004; 63(2):226-31. PubMed ID: 15236779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulating the regulators in cancer-immunosuppression in multiple myeloma (MM).
    Feyler S; Selby PJ; Cook G
    Blood Rev; 2013 May; 27(3):155-64. PubMed ID: 23623928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment and characterization of a CD5 positive, immunosuppressive human myeloma cell line.
    Scibienski RJ; Paglieroni TG; MacKenzie MR
    Leukemia; 1990 Nov; 4(11):775-80. PubMed ID: 1700238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoregulatory circuits in myeloma.
    Ullrich S; Zolla-Pazner S
    Clin Haematol; 1982 Feb; 11(1):87-111. PubMed ID: 7042151
    [No Abstract]   [Full Text] [Related]  

  • 17. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
    Greil R; Egle A; Villunger A
    Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of myeloma growth in BALB-c mice by injection of anti-immunoglobulin antisera.
    Manning DD; Jutila JW
    J Immunol; 1974 Jul; 113(1):78-83. PubMed ID: 4208925
    [No Abstract]   [Full Text] [Related]  

  • 19. New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma.
    Neri P; Bahlis NJ; Lonial S
    Clin Cancer Res; 2016 Dec; 22(24):5959-5965. PubMed ID: 27797968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in immunotherapy in multiple myeloma.
    Boussi L; Niesvizky R
    Curr Opin Oncol; 2017 Nov; 29(6):460-466. PubMed ID: 28877078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.